This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch

Editor’s Note:
**Milestones, Perspectives**

With 161 Votes in Favour, 8 Abstentions, General Assembly Adopts Landmark Resolution Recognizing Clean, Healthy, Sustainable Environment as Human Right

28 July 2022

GA/12437

With 161 votes in favour and 8 abstentions, the General Assembly adopted a landmark resolution today recognizing the right to a clean, healthy and sustainable environment as a human right and calling for greater global efforts to ensure that principle is upheld.

Affirming that promoting that right requires the full implementation of the multilateral environmental agreements, the 193-member body called upon States, international organizations, business enterprises and other relevant stakeholders to adopt policies, enhance international cooperation, strengthen capacity-building and continue to share good practices in order to scale up efforts to ensure a clean, healthy and sustainable environment for all.

The representative of Costa Rica, introducing the text, underscored that with the world facing an unprecedented triple environmental crisis — of climate change, biodiversity loss and pollution — the universal recognition of the human right to a clean, healthy and sustainable environment provides a powerful, effective response that could catalyse transformative changes in societies.

Prior to the text’s adoption, several delegates stressed that there is no common internationally agreed understanding on the content and scope for the right to a clean, healthy and sustainable environment, with the Russian Federation’s representative stressing that States can only talk about a legally recognized right after such right is recognized exclusively within international treaties...

Hailing General Assembly Historic Resolution on Healthy, Sustainable Environment, Secretary-General Urges States to Make Text ‘a Reality for Everyone, Everywhere’

28 July 2022

SG/SM/21386

The following statement was issued today by the Spokesman for UN Secretary-General António Guterres:

The Secretary-General welcomes the adoption by the General Assembly of its historic resolution recognizing the right to a clean, healthy and sustainable environment.

This landmark development demonstrates that Member States can come together in our collective fight against the triple planetary crises of climate change, biodiversity loss, and pollution. The international community has given universal recognition to this right and brought us closer to making it a reality for all.
The resolution will help reduce environmental injustices, close protection gaps and empower people, especially those that are in vulnerable situations, including environmental human rights defenders, children, youth, women and indigenous peoples. The resolution will also help States accelerate the implementation of their environmental and human rights obligations and commitments.

However, the adoption of the resolution is only the beginning. The Secretary-General urges States to make the right to a clean, healthy and sustainable environment a reality for everyone, everywhere.

---

Immunisation in lower-income countries: pandemic leads to decline in coverage but signs of recovery emerge - Gavi

:: New analysis of the state of routine immunisation in lower-income countries underlines impact of COVID-19 pandemic, but signs of recovery are emerging.
:: Basic vaccine coverage in 57 Gavi-supported countries dropped by one percentage point to 77% in 2021 following a four percentage point fall in 2020; number of zero-dose children increased by 570,000 to 12.5 million.
:: One-third of the countries analysed saw vaccine coverage increase in 2021. Two-thirds of African countries have either recovered to pre-pandemic levels or begun recovering. Chad and Pakistan stand out for strong performances.

Geneva, 29 July 2022 – An analysis of the state of routine immunisation in 57 lower-income countries supported by Gavi shows that the COVID-19 pandemic continued to hold back vaccinations in 2021, however signs of recovery are beginning to emerge.

Basic vaccine coverage in lower-income countries dropped by one percentage point to 77% after a four percentage-point fall in 2020, the first year of the pandemic. The number of zero-dose children, who have not received a single shot of basic vaccines, rose for the second year running to 12.5 million. The overall decline since 2019 is primarily driven by larger countries such as the Democratic Republic of the Congo – which, after a strong growth trajectory in previous years, fell from vaccinating 73% of children in 2019 to 65% in 2021 – and India, which dropped from a high coverage level of 91% to 85%. The Democratic People’s Republic of Korea, Myanmar and Mozambique all saw large declines in coverage in 2021.

“Hiding behind these figures is a human tragedy on an enormous scale” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Millions of children have missed out on lifesaving vaccines, leaving them vulnerable to some of the world’s deadliest diseases. Gavi will continue to stand shoulder to shoulder with countries to get immunisation back on track, because no parent should have to suffer the loss of their child due to preventable illness.”

However, elsewhere there are signs of recovery emerging. One-third, or 19 of the 57 countries included in the analysis, increased vaccine coverage in 2021. Chad and Niger both increased coverage across the pandemic period from 2019-2021, reducing the number of zero-dose children by 16 and 20% respectively, while Pakistan saw strong recovery in 2021 and reduced the number of zero-dose children by more than 400,000, bringing numbers back to pre-pandemic levels.
“This analysis represents a very sobering assessment of the impact the pandemic continues to have on essential routine immunisation,” said Anuradha Gupta, Deputy CEO of Gavi, the Vaccine Alliance. “It was expected in 2020 that lockdowns and other disruptions would take a toll, and in 2021, more than half of Gavi implementing countries have increased or maintained coverage – working hard to restore and recover immunisation services. However, it is clear some countries are taking longer than others. Another challenge will be the increasing birth cohort in Africa, which means immunisation programmes in this region will need to continuously accelerate to maintain and expand coverage levels. As the Vaccine Alliance, we must use these insights to provide tailored support where it is needed most: this means learning from those countries, such as Chad or Pakistan, that have demonstrated strong progress, and understanding better why other countries may be falling behind.”

The analysis, by Gavi, the Vaccine Alliance, used data from the recently published WHO/UNICEF Estimates of National Immunisation Coverage (WUENIC) to examine the state of routine immunisation in the 57 lower-income countries supported by Gavi.

Other key insights include:
:: Since its inception in 2000 until the end of 2021, Gavi, the Vaccine Alliance has helped to immunise more than 981 million children with routine vaccines, helping to halve child mortality across 73 lower-income countries.
:: Including COVID-19 vaccinations, lower-income countries administered more vaccines in 2021 than any year in history. In 2021, the countries that have received Gavi support administered routine vaccines to 65 million children. In addition, the 57 countries currently supported by the Vaccine Alliance administered more than two billion COVID-19 vaccines.
:: Fragile and conflict-affected countries saw a lower decline in vaccine coverage than other countries, with the 12 countries classed as such by Gavi maintaining coverage at 67% over the course of 2021.
:: Coverage for rotavirus vaccine, the second dose of measles vaccine and pneumococcal conjugate vaccine in lower-income countries have all increased since 2019, despite the pandemic.
:: However, school closures and supply issues contributed to a major decline in coverage for the first dose of human papillomavirus (HPV) vaccine, which protects against cervical cancer. Globally just 12% of girls now receive this crucial vaccine.
:: Demographics continue to cause challenges to routine immunisation programmes. The birth cohort in Gavi-supported countries in Africa rose by 1.2 million between 2019 and 2021, meaning immunisation programmes have to reach more children each year just to maintain coverage levels...

::::

Editor’s Note
The informative Gavi analysis above – focused on Gavi-supported countries – is issued two weeks after the broader WHO announcement/analysis below, which we carried in our 17 July 2022 edition. We repeat it here to provide context.

COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades - WHO
GENEVA/NEW YORK, 15 July 2022 – The largest sustained decline in childhood vaccinations in approximately 30 years has been recorded in official data published today by WHO and UNICEF.
The percentage of children who received three doses of the vaccine against diphtheria, tetanus and pertussis (DTP3) – a marker for immunization coverage within and across countries – fell 5 percentage points between 2019 and 2021 to 81 per cent.

As a result, 25 million children missed out on one or more doses of DTP through routine immunization services in 2021 alone. This is 2 million more than those who missed out in 2020 and 6 million more than in 2019, highlighting the growing number of children at risk from devastating but preventable diseases.

The decline was due to many factors including an increased number of children living in conflict and fragile settings where immunization access is often challenging, increased misinformation and COVID-19 related issues such as service and supply chain disruptions, resource diversion to response efforts, and containment measures that limited immunization service access and availability.

“This is a red alert for child health. We are witnessing the largest sustained drop in childhood immunization in a generation. The consequences will be measured in lives,” said Catherine Russell, UNICEF Executive Director. "While a pandemic hangover was expected last year as a result of COVID-19 disruptions and lockdowns, what we are seeing now is a continued decline. COVID-19 is not an excuse. We need immunization catch-ups for the missing millions or we will inevitably witness more outbreaks, more sick children and greater pressure on already strained health systems.”

18 million of the 25 million children did not receive a single dose of DTP during the year, the vast majority of whom live in low- and middle-income countries, with India, Nigeria, Indonesia, Ethiopia and the Philippines recording the highest numbers. Among countries[1] with the largest relative increases in the number of children who did not receive a single vaccine between 2019 and 2021 are Myanmar and Mozambique.

Globally, over a quarter of the coverage of HPV vaccines that was achieved in 2019 has been lost. This has grave consequences for the health of women and girls, as global coverage of the first dose of human papillomavirus (HPV) vaccine is only 15%, despite the first vaccines being licensed over 15 years ago.

It was hoped that 2021 would be a year of recovery during which strained immunization programmes would rebuild and the cohort of children missed in 2020 would be caught-up. Instead, DTP3 coverage was set back to its lowest level since 2008 which, along with declines in coverage for other basic vaccines, pushed the world off-track to meet global goals, including the immunization indicator for the Sustainable Development Goals.

This historic backsliding in rates of immunization is happening against a backdrop of rapidly rising rates of severe acute malnutrition. A malnourished child already has weakened immunity and missed vaccinations can mean common childhood illnesses quickly become lethal to them. The convergence of a hunger crisis with a growing immunization gap threatens to create the conditions for a child survival crisis.

Vaccine coverage dropped in every region, with the East Asia and Pacific region recording the steepest reversal in DTP3 coverage, falling nine percentage points in just two years.
“Planning and tackling COVID-19 should also go hand-in-hand with vaccinating for killer diseases like measles, pneumonia and diarrhea,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “It’s not a question of either/or, it’s possible to do both”.

**Some countries notably held off declines.** Uganda maintained high levels of coverage in routine immunization programmes, whilst rolling out a targeted COVID-19 vaccination programme to protect priority populations, including health workers. Similarly, Pakistan returned to pre-pandemic levels of coverage thanks to high-level government commitment and significant catch-up immunization efforts. To achieve this in the midst of a pandemic, when healthcare systems and health workers were under significant strain, should be applauded.

Monumental efforts will be required to reach universal levels of coverage and to prevent outbreaks. Inadequate coverage levels have already resulted in avoidable outbreaks of measles and polio in the past 12 months, underscoring the vital role of immunization in keeping children, adolescents, adults, and societies healthy.

First dose measles coverage dropped to 81 per cent in 2021, also the lowest level since 2008. This meant 24.7 million children missed their first measles dose in 2021, 5.3 million more than in 2019. A further 14.7 million did not receive their needed second dose. Similarly, compared to 2019, 6.7 million more children missed the third dose of polio vaccine and 3.5 million missed the first dose of the HPV vaccine - which protects girls against cervical cancer later in life.

The sharp two-year decline follows almost a decade of stalled progress, underscoring the need to not only address pandemic-related disruptions but also systemic immunization challenges to ensure every child and adolescent is reached.

WHO and UNICEF are working with Gavi, the Vaccine Alliance and other partners to deliver the global Immunization Agenda 2030 (IA2030), a strategy for all countries and relevant global partners to achieve set goals on preventing diseases through immunization and delivering vaccines to everyone, everywhere, at every age.

“It’s heart-breaking to see more children losing out on protection from preventable diseases for a second year in a row. The priority of the Alliance must be to help countries to maintain, restore and strengthen routine immunization alongside executing ambitious COVID-19 vaccination plans, not just through vaccines but also tailored structural support for the health systems that will administer them,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.

**The IA2030 partners call on governments and relevant actors to:**
- **Intensify efforts for catch-up vaccination** to address backsliding on routine immunization, and expand outreach services in underserved areas to reach missed children and implement campaigns to prevent outbreaks;
- **Implement evidence-based, people-centred, and tailored strategies to build trust** in vaccines and immunization, counter misinformation and increase vaccine uptake particularly among vulnerable communities;
- **Ensure current pandemic preparedness and response** and the global health architecture strengthening efforts lead to investment in primary health care (PHC) services, with explicit support to strengthen and sustain essential immunization;
- **Ensure political commitment** from national governments and increase domestic resource allocation to strengthen and sustain immunization within PHC;
- **Prioritize health information and disease surveillance systems strengthening** to provide the data and monitoring needed for programmes to have maximum impact; and
- Leverage and increase investment in research to **develop and improve new and existing vaccines and immunization services** that can achieve community needs and deliver on IA2030 goals.

---

**PHEIC**

**Monkeypox**

**Multi-country outbreak of monkeypox, External situation report #2 - 25 July 2022**

*Edition 2*

25 July 2022 | Emergency Situational Updates

**Overview**

This is the second situation report for the multi-country outbreak of monkeypox, which provides details on the latest epidemiology, updates from the Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee, new guidance documents and updates on WHO advice.

**Highlights**

- The International Health Regulations Emergency Committee on the multi-country outbreak of monkeypox held its second meeting on 21 July 2022. Having considered the views of Committee Members and Advisors as well as other factors in line with the International Health Regulations (2005), the WHO Director-General on 23 July 2022 declared this outbreak a public health emergency of international concern and issued Temporary Recommendations in relation to the outbreak. He stated that “we have an outbreak that has spread around the world rapidly, through new modes of transmission, about which we understand too little, and which meets the criteria in the International Health Regulations...[T]his is an outbreak that can be stopped with the right strategies in the right groups.” He issued temporary recommendations for countries to stop transmission and bring the outbreak under control.

- **All six WHO Regions have now reported cases of monkeypox. Since the situation report published on 6 July, the South-East Asia Region reported confirmed cases.**

- In the African Region, the latest data on monkeypox indicate a significant increase in cases since April 2022, compared to the same period in 2021, which could, in turn, be attributed to enhanced monkeypox surveillance and laboratory testing capacity in the countries. The highest number of suspected cases of monkeypox in the region had been reported in 2020.

- WHO has launched a global epidemiological report titled “Multi-Country Monkeypox Outbreak - Global Trends” that is updated at least twice weekly, and the geographic distribution of cases can be viewed using the WHO Health Emergency Dashboard. The Report focuses on case report forms provided by the Member States to WHO, as outlined in the Surveillance, case investigation, and contact tracing for Monkeypox interim guidance. The Dashboard provides the latest aggregate cases and deaths reported by the Member States, updated daily. These two data products complement this Situation Report, which is produced every two weeks and provides a more
comprehensive update of the monkeypox outbreak beyond the epidemiological information; and which itself is a successor of the previous Disease Outbreak News reports on monkeypox...

Figure 1. Epidemiological curve of weekly aggregated confirmed cases of monkeypox by region, from 1 January 2022 to 22 July 17:00 CEST*

*This figure shows aggregated weekly data, for epidemiological weeks ending on Sundays. Data on the current week, with incomplete data, will be presented in the next situation report.

-----

**PHEIC**

*Coronavirus [COVID-19] - WHO*

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

*Weekly Epidemiological and Operational updates*

_Last update: 29 Jul 2022_

**Confirmed cases ::**

572 239 451

**Confirmed deaths ::**

6 390 401

**Vaccine doses administered:**

12 248 795 623

-----

**Weekly epidemiological update on COVID-19 – 27 July 2022**

*Overview*

Globally, the number of weekly cases reported during the week of 18 to 24 July 2022 was similar to the number reported last week, with over 6.6 million new cases. Likewise, the number of new weekly
deaths was similar to the number reported during the previous week, with over 12,600 fatalities. As of 24 July 2022, over 567 million confirmed cases and over 6.3 million deaths have been reported globally.

In this edition, we include:
:: The COVID-19 epidemiological update at the global and regional levels.
:: An update on the circulating SARS-CoV-2 variants of concern (VOCs), including their geographic spread and prevalence.

![COVID-19 cases reported weekly by WHO Region, and global deaths, as of 24 July 2022](image)

---

**Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022**

[New additions; Full scale view available at title link above]

---

**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 30 Jul 2022**

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

| **Vaccines approved for use by at least one national regulatory authority** | 39 |
| **Vaccines in WHO’s Emergency Use Listing** | 11 |
| **Doses secured globally** | 17.7bn |
| **Reported vaccine price range per dose** | $2-$40 |
| **Doses COVAX has secured, optioned, or received as donations** | 2.8bn |
| **Doses shipped through COVAX to 146 countries** | 1.59bn |

---

**Global Dashboard on COVID-19 Vaccine Equity**
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 30 Jul 2022]: [https://data.undp.org/vaccine-equity/](https://data.undp.org/vaccine-equity/)
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)

---

**COVID-19 Global Targets and Progress Tracker** - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

---

**Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)**
**Duke – Launch and Scale Speedometer**  
**The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research  
See our COVID Vaccine Manufacturing research  
See our COVID Vaccine Donations & Exports research

---

**Overview of donations by top 10 donating countries**

Bar chart is ordered by total number of doses pledged. Donut charts are ordered by proportion of pledged donations shipped.

Country Category: Top 10 Donating Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Pledged doses</th>
<th>Total Shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>3,200,000,000</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>266,000,000</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>175,000,000</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>120,000,000</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>100,000,000</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>100,000,000</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>77,000,000</td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td>60,000,000</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>60,000,000</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>54,000,000</td>
<td></td>
</tr>
</tbody>
</table>

Number of Doses

Italy
- 72% shipped

Germany
- 69% shipped

Japan
- 69% shipped

Australia
- 64% shipped

France
- 64% shipped

China
- 54% shipped

Spain
- 50% shipped

United States
- 48% shipped

United Kingdom
- 41% shipped

Canada
- 33% shipped

Remaining: 1,160,769,088  
Total Shipped: 1,375,631,580

Data updated on July 29th 2022
COVID Vaccines — OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
30 Jul 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 115M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.3B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 340M
Other Delivered (Number of Doses): 370M
Total Delivered (Number of Doses): 710M
Total Administered (Number of Doses): 480M

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 30 Jul 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 30 Jul 2022]

:: 67% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.34 billion doses have been administered globally, and 7.75 million are now administered each day.
:: Only 19.9% of people in low-income countries have received at least one dose.

**U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**

**News**

*Biden-Harris Administration Secures 66 Million Doses of Moderna’s Variant-Specific COVID-19 Vaccine Booster for Potential Use in Fall and Winter 2022*
July 29, 2022 | News Release

*HHS Expands Availability of Monkeypox Vaccine to More Than 1.1 Million Doses*
July 28, 2022 | News Release

*Statement by HHS Secretary Becerra on FDA Approval of Additional Bavarian Nordic Monkeypox Vaccine*
July 27, 2022 | News Release
The FDA has been closely tracking reports of monkeypox transmissions in the United States with our federal public health partners and coordinating preparedness efforts accordingly,” said FDA Commissioner Robert M. Califf, M.D. “We understand that while we are still living with COVID-19, an emerging disease may leave people feeling concerned and uncertain, but it’s important to note that we already have medical products in place, specifically an FDA-approved vaccine for the prevention of monkeypox disease and an FDA-cleared diagnostic test. The FDA is using the full breadth of its authorities to make additional diagnostics and treatments available. We will continue to collaborate with our partners across all sectors to expand accessibility to countermeasures and bolster the tools in our arsenal as appropriate.”...
Monitoring - 29 Jul 2022

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Latest [Selected]
Press release 25 July 2022
EU wins WTO case against Turkey's discriminatory practices on pharmaceuticals
The EU welcomes today's appeal arbitration award by the World Trade Organization (WTO) in the case the EU brought against Turkey on pharmaceutical products.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.
India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
COVID - 19 Vaccination Update - Day 561
:: India’s cumulative vaccination coverage crosses 204.23 Crore
:: More than 27 lakh Vaccine doses administered today till 7 pm
Posted On: 30 JUL 2022 8:39PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations, leading us to include these reports/observations from the general media below. See China CDC below for additional announcements]

Covid in China: Million in lockdown in Wuhan after four cases
By Yaroslav Lukov
BBC News, 28 Jul 2022
Almo st one million people in a suburb of Wuhan - China's central city where the coronavirus was first recorded - have been placed under lockdown.
Jiangxia district residents have been ordered to stay inside their homes or compounds for three days after four asymptomatic Covid cases were detected...
Polio this week as of 26 July 2022

:: Last week, a polio case was detected in New York, USA. The CDC has been coordinating with New York State health authorities on their investigations and response. Any form of poliovirus anywhere in the world is a threat to countries everywhere. More.
:: In Mozambique, three new wild poliovirus type 1 (WPV1) cases are reported this week, including one case from a district bordering Zimbabwe. See ‘Mozambique’ section below, for more information.
:: “Women front line workers in Pakistan have resolved to reach all children with polio vaccine, even if it means crossing difficult terrain. As a polio gender champion, I urge all parents and caregivers to vaccinate their children and end polio once and for all.” Amanda Milling, UK Minister for Asia and the Middle East and Polio Gender Champion. Read more...
:: Analysis of 2021 data: In 2021, more than 372 million children were vaccinated multiple times in 30 countries, using more than 1 billion doses of OPV.

Summary of new polioviruses this week:
:: Pakistan: one WPV1 case
:: Benin: one cVDPV2 positive environmental sample
:: Chad: one cVDPV2 case
:: DR Congo: one cVDPV2 case
:: Madagascar: three cVDPV1 cases
:: Mozambique: three WPV1 cases and two cVDPV1 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Snapshot of Population Movements, January to July 2022 (As of 26 July 2022)

Northern Ethiopia
Ethiopia - Situation Report, 22 Jul 2022

Ukraine
Ukraine: Situation Report - Last updated: 27 July 2022

WHO & Regional Offices [to 30 Jul 2022]
https://www.who.int/news
Selected News/Announcements/Statement
29 July 2022
Departmental news
Regional gatherings to strengthen pandemic influenza preparedness
Afghanistan influenza surveillance system stands solid

WHO publishes new guidelines on HIV, hepatitis and STIs for key populations

WHO and UNAIDS support countries to introduce virtual interventions and HIV self-testing

WHO consultation on guidance development for conducting TB programme reviews

WHO recommends long-acting cabotegravir for HIV prevention

WHO applauds agreement to scale-up generic manufacturing for access to long-acting injectable antiretrovirals

HIV response under threat – new figures

Building a community of learning for women leaders in health emergencies

New US$ 1 price for HIV self-tests

WHO launched new implementation guidance for simplified and differentiated service delivery of pre-exposure prophylaxis (PrEP)

Guidance, tools and support for countries transitioning to digital, case-based surveillance for TB

......
WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected
WHO Director-General’s opening remarks at the COVID-19 media briefing – 27 July 2022

WHO Director-General’s statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox - 23 July 2022

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: 91 million Africans infected with Hepatitis B or C 27 July 2022

WHO Region of the Americas PAHO
:: On World Hepatitis Day, Guyana scales up efforts towards the elimination of viral hepatitis
28 July 2022 (PAHO) – To mark World Hepatitis Day, Guyana is launching its first hepatitis C treatment program. With the technical cooperation and support of the Pan American Health Organization (PAHO), Guyana is receiving rapid testing kits as well as life-saving medicines. "Viral hepatitis remains a global public health threat and Guyana’s…
:: COVID-19 stabilizes in the region, but countries must remain vigilant against the virus, manage other health emergencies, PAHO Director says
27 Jul 2022With monkeypox infections reaching over 5000, and a case of polio type 2 reported in the United States, vaccines, medicines and surveillance are key Washington D.C. 27 July 2022 (PAHO) – While COVID-19 cases decreased in the Americas for the first time in five weeks, the Pan American Health Organization (PAHO) Director, Carissa F Etienne, has...

WHO South-East Asia Region SEARO
:: 28 July 2022 Statement
World Hepatitis Day: Bring hepatitis care closer to you

WHO European Region EURO
:: 26 July 2022 Statement
Statement: Vaccines alone won’t end the monkeypox outbreak – at-risk individuals will have to take action too
:: 24 July 2022 News release
Responding to the monkeypox outbreak: perspectives of clinicians treating patients with the disease

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

::: WHO Events 
https://www.who.int/news-room/events/1
[Selected]

**WHO Monkeypox Research - What study designs can be used to address the remaining knowledge gaps for monkeypox vaccines?**
2 August 2022 13:00 – 18:00 UTC Time

**SDG 11.6.2 Working Group: Final Meeting**
3 August 2022 14:00 – 16:00 CET

**Launch event: "Implication of the COVID-19 Pandemic for Patient Safety: a rapid review"**
9 August 2022 14:00 – 15:30 CET

**Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 11 August 2022**
11 August 2022

::: New WHO Publications
https://www.who.int/publications/i

**Selected Titles**
29 July 2022

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care...

29 July 2022

Digital adaptation kit for HIV: operational requirements for implementing WHO recommendations and standards...

29 July 2022

Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact

29 July 2022

Policy brief: Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment...

28 July 2022

Malaria chemoprevention efficacy study protocol
28 July 2022
Emergency in Ukraine: external situation report #18, published 28 July 2022: reporting period: 14–27...

28 July 2022
Guidelines on long-acting injectable cabotegravir for HIV prevention

27 July 2022
Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation...

26 July 2022
Report of the fifth meeting of the WHO STAGE for MCA and Nutrition, 10-12 May 2022

26 July 2022
Update on the transition to dolutegravir-based antiretroviral therapy

25 July 2022
Standard operating procedures for supply chain management of health products for neglected tropical diseases...

25 July 2022
Priorities for antiretroviral drug optimization in adults and children report of a CADO, PA DO and HIVResNet...

25 July 2022
Virtual Meeting of Regional Technical Advisory Group for dengue and other arbovirus diseases, New Delhi,...

24 July 2022
Implementation guide for vaccination of health workers

::::::

CDC/ACIP [U.S.] [to 30 Jul 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases

::::::

ACIP Meetings
Next ACIP Meeting
October 19-20
:: Progress Toward the Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Worldwide, 2016–2021


Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 15 announcements/reports/data summaries.

Africa CDC [to 30 Jul 2022]
http://www.africacdc.org/
News
Press Releases
Multi-country monkeypox outbreak declared a global Public Health Emergency of International Concern
25 July 2022

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 30 Jul 2022]
http://en.nhc.gov.cn/
News
Chinese mainland reports 60 new local confirmed COVID-19 cases
2022-07-29
The Chinese mainland on Thursday reported 60 locally transmitted confirmed COVID-19 cases, including 21 in Gansu province, the National Health Commission said Friday.

National Medical Products Administration – PRC [to 30 Jul 2022]
http://english.nmpa.gov.cn/
News
Chinese mainland reports 60 new local confirmed COVID-19 cases
2022-07-29
The Chinese mainland on Thursday reported 60 locally transmitted confirmed COVID-19 cases, including 21 in Gansu province, the National Health Commission said Friday.
COVID-19 ISSUE (28)

:: Preplanned Studies: Association Between COVID-19 Vaccination Coverage and Case Fatality Ratio: a Comparative Study — Hong Kong SAR, China and Singapore, December 2021–March 2022
:: Outbreak Reports: Response and Assessment of the Effectiveness of the Countermeasures for a COVID-19 Outbreak — Guizhou Province, China, March 2022
:: Methods and Applications: Estimating New Cases Among Athletes During the Winter Olympics Based on a Dynamic Model — Beijing, China, February 2022
:: Notes from the Field: First Imported Case of SARS-CoV-2 Omicron Subvariant BA.5 — Shanghai Municipality, China, May 13, 2022
:: Notes from the Field: The First Outbreak of Omicron Subvariant BA.5.2 — Beijing Municipality, China, July 4, 2022
:: Notes from the Field: An Outbreak of the SARS-CoV-2 Omicron Variant BA.1 — Zhuhai City, Guangdong Province, China, January 13, 2022

Organization Announcements

Editor's Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 30 Jul 2022]
https://alleninstitute.org/news-press/
News
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease
July 28, 2022

BMGF - Gates Foundation [to 30 Jul 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 30 Jul 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

**CARB-X** [to 30 Jul 2022]
https://carb-x.org/
News
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 30 Jul 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of *Vaccines and Global Health: The Week in Review* are available here.
:: **Informed Consent: A Monthly Review – July 2022** is now posted [here](#).
:: **Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022** is now posted [here](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 30 Jul 2022]
http://cepi.net/
Latest News
**CEPI, UK MHRA, and UK Health Security Agency to advance key tools for Monkeypox vaccine research**
   Up to US$375k will be made available by CEPI for the development of a Monkeypox antibody standard and assays.
News  28 Jul 2022

**CEPI statement: CEO welcomes White House Summit on the Future of COVID-19 Vaccines**
   Dr Richard Hatchett calls for heightened investment to develop the next generation of globally accessible COVID-19 vaccines
News  26 Jul 2022

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 30 Jul 2022]
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 30 Jul 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP** [to 30 Jul 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

News
29 July 2022
**EDCTP Annual Report 2021: achieving excellence and equity in global health research**

26 July 2022
**EDCTP National Health Research Systems 2020 survey report**

**Emory Vaccine Center**  [to 30 Jul 2022]  
http://www.vaccines.emory.edu/  
Vaccine Center News  
**No new digest content identified.**

**European Vaccine Initiative**  [to 30 Jul 2022]  
http://www.euvaccine.eu/  
**Latest News, Events**  
**No new digest content identified.**

**Evidence Aid**  [to 30 Jul 2022]  
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.  
http://www.evidenceaid.org/  
**Selected Resources**  
**Physical interventions to prevent the spread of respiratory viruses (search done in April 2020)**  
Added July 28, 2022  

**Interventions to overcome limited supply of masks (search done in June 2020)**  
Added July 27, 2022  

**Personal protective equipment for surgeons during the COVID-19 pandemic (search done in April 2020)**  
Added July 26, 2022  

**Fondation Merieux**  [to 30 Jul 2022]  
http://www.fondation-merieux.org/  
**News, Events**  
**No new digest content identified**

**Gavi**  [to 30 Jul 2022]
29 July 2022

**Immunisation in lower-income countries: pandemic leads to decline in coverage, but signs of recovery emerge**

[See Milestones above for detail]

29 July 2022

**Global monkeypox outbreak underlines need for vigilance, engagement and solidarity with partners, countries and civil society**

**GHIT Fund** [to 30 Jul 2022]

https://www.ghitfund.org/newsroom/press

Press Releases

*No new digest content identified*

**Global Fund** [to 30 Jul 2022]


News & Stories

29 July 2022

**As Progress Against HIV Slows, Global Fund Calls for Accelerated Investments in Innovations**

The Global Fund to Fight AIDS, Tuberculosis and Malaria is deeply concerned about the slowdown of the global fight against HIV. A new UNAIDS report released this week at the International AIDS Conference in Montreal shows that progress against the di...
Fifty-one graduate students and their advisers are joining the thriving community supported by the HHMI Gilliam Fellowships for Advanced Study.

**Human Vaccines Project** [to 30 Jul 2022]
http://www.humanvaccinesproject.org/
News
What’s New  [Selected]
No new digest content identified.

**IAVI** [to 30 Jul 2022]
https://www.iavi.org/
Latest News
FEATURES
July 27, 2022
Read: **WHO preferred product characteristics for monoclonal antibodies (mAbs) for HIV prevention**

**ICRC** [to 30 Jul 2022]
What’s New  [Selected]
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
Selected Statements, Press Releases, Research
No new digest content identified.

**IFFIm**
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

**IFRC** [to 30 Jul 2022]
Press Releases [Selected]
No new digest content identified.

**Institut Pasteur** [to 30 Jul 2022]
Press Documents
No new digest content identified.
**IOM / International Organization for Migration** [to 30 Jul 2022]

*News*
25 Jul 2022

**New Guidelines to Provide First Global Policy Framework on Protecting Children on the Move in Face of Climate Change**

**ISC / International Science Council** [to 30 Jul 2022]
https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

*News*

**Press releases**

**Liaison Committee appointed for the ISC Regional Focal Point for the Latin American and Caribbean Region**
29.07.2022

*News*

**2022 International Open Access Week will focus on ‘Open for Climate Justice’**
26.07.2022

**International Union of Immunological Societies (IUIS)**
https://iuis.org/

*News/Events [Selected]*

No new digest content identified.

**IVAC** [to 30 Jul 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

No new digest content identified.

**IVI** [to 30 Jul 2022]
http://www.ivi.int/

**IVI News & Announcements**

**First ‘Introductory Course for Biologics Development and Manufacturing’ completes training of 106 participants from 24 countries, and 32 Koreans**

:: Africa CDC’s PAVM provided travel scholarships to 50 trainees from 14 African countries
:: IVI to conduct the ‘2022 Introductory Course for Standard Practice (GxP Course)’ in October to educate 300 trainees and bridge basic knowledge with hands-on training

July 29, 2022
Johns Hopkins Center for Health Security [to 30 Jul 2022]
https://www.centerforhealthsecurity.org/newscenter-news/
Center News
No new digest content identified.

MSF/Médecins Sans Frontières [to 30 Jul 2022]
http://www.msf.org/
Latest [Selected Announcements]
Chad
**Co-designing health programmes with the community in Chad**
Project Update 27 Jul 2022

National Academy of Medicine - USA [to 30 Jul 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 30 Jul 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 30 Jul 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 30 Jul 2022]
http://www.nih.gov/
News Releases
**New insights into HIV latent cells yield potential cure targets**
July 27, 2022 — Researchers used cutting-edge technology to reveal new insights into cellular reservoirs of HIV.

PATH [to 30 Jul 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Rockefeller Foundation [to 30 Jul 2022]
The Rockefeller Foundation’s Pandemic Prevention Institute and the Pasteur Network Partner to Strengthen Global Disease Surveillance

Washington, D.C., Paris | July 26, 2022 – The Rockefeller Foundation’s Pandemic Prevention Institute (PPI) and the Pasteur Network have signed a Memorandum of Understanding (MoU) to advance early detection and reporting for emerging and reemerging diseases and build a robust decentralized global surveillance network that strengthens local capacity for sharing high-quality data across countries. The collaboration aims to enhance the effectiveness of the Pandemic Prevention Institute and the Pasteur Network’s 33 member institutions in both addressing infectious diseases, such as Covid-19 and monkeypox, and informing interventions against them...

Sabin Vaccine Institute [to 30 Jul 2022]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 30 Jul 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
30 July 2022
It is time to end AIDS in children once and for all: Global Alliance launched

UNHCR Office of the United Nations High Commissioner for Refugees [to 30 Jul 2022]
Selected News Releases, Announcements
UNHCR highlights key concerns for refugee health amid record displacement
Despite troubling rates of malnutrition, gains were noted in the inclusion of refugees in national health policies
29 Jul 2022

UNICEF [to 30 Jul 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
25 July 2022
New guidelines provide first global policy framework on protecting children on the move in face of climate change
University have today launched new guidelines to provide the first-ever global policy framework that will help protect, include, and empower children on the move...

Unitaid [to 30 Jul 2022]
https://unitaid.org/
Featured News
30 July 2022
**Pooled data analysis from three large-scale clinical trials reveal long-term effects of dolutegravir-based treatment regimens on people living with HIV**

28 July 2022
**AVAC, CIFF, MedAccess, Unitaid, and ViiV Healthcare announce collaboration to catalyse more affordable access to long-acting injectable cabotegravir for HIV prevention**

28 July 2022
**A new agreement will allow for generic production of first and only long-acting injectable HIV prevention in 90 countries where majority of new HIV infections occur**

27 July 2022
**World Hepatitis Day: Unitaid reaffirms its commitment to make hepatitis C elimination a reality by putting affected people at the heart of the response**

Vaccine Equity Cooperative [nee Initiative] [to 30 Jul 2022]
https://vaccineequitycooperative.org/news/
News
*No new digest content identified.*

Vaccination Acceptance & Demand Initiative [Sabin] [to 30 Jul 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
*No new digest content identified.*

Vaccine Confidence Project [to 30 Jul 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
News
*No new digest content identified.*

Vaccine Education Center – Children’s Hospital of Philadelphia [to 30 Jul 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
**Vaccine Update for Providers**
July 2022
News & views — Monkeypox: What you should know

Wellcome Trust  [to 30 Jul 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
Opinion
Author - Charlie Weller
The biggest immunisation decline in a generation shows why we need to get ahead of escalating infectious diseases
25 July 2022

The Wistar Institute  [to 30 Jul 2022]
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations  [to 30 Jul 2022]
https://www.wfpha.org/
Latest News - Blog
Protecting Health Workforce through Vaccination in LICs and LMICs
Jul 26, 2022
Protecting Health Workforce through Vaccination in LICs and LMICs
Successful national immunization programs depend on up-to-date policies and effective strategies at all levels to achieve and maintain coverage targets, as well as to develop...

World Bank  [to 30 Jul 2022]
Selected News, Announcements
World Bank Scales Up its Financing for Food Security with Additional $315 Million to Strengthen the Resilience of Food Systems across West Africa
WASHINGTON, July 29, 2022 - Some additional 2 million people will benefit from a second phase of the West Africa regional Food Systems Resilience Program (FSRP-2) approved today for a total amount...
Date: July 29, 2022 Type: Press Release

World Customs Organization – WCO  [to 30 Jul 2022]
http://www.wcoomd.org/
Latest News
28 July 2022
WTO high-level event examines how international cooperation can tackle illicit trade
25 July 2022
Current monkeypox outbreak declared a Public Health Emergency of International Concern
World Organisation for Animal Health (OIE)  [to 30 Jul 2022]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

WTO - World Trade Organisation  [to 30 Jul 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
WTO issues latest edition of Annual Report
28 July 2022
The WTO has published the latest edition of its Annual Report, providing a comprehensive account of the organization’s activities in 2021 and early 2022. The report also covers the successful conclusion of the 12th Ministerial Conference (MC12), which was originally scheduled for end-2021 but postponed until June 2022.

Heads of multilateral agencies outline central role in addressing multiple crises
27 July 2022
The WTO, the International Monetary Fund (IMF), the World Bank, the European Bank for Reconstruction and Development (EBRD) and the Asian Development Bank (ADB) outlined on 27 July the role they play in supporting sustainable development and helping developing economies respond to the COVID-19 pandemic, the war in Ukraine and climate and energy-related crises. The session held at the Aid for Trade Global Review looked at where Aid for Trade financing is being directed, what it is achieving and how future priorities should balance short-term pressures with longer-term needs.

:::::

ARM [Alliance for Regenerative Medicine]  [to 30 Jul 2022]
Selected Press Releases
No new digest content identified.

BIO  [to 30 Jul 2022]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 30 Jul 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 30 Jul 2022]
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine (28 July 2022)

LONDON and GENEVA – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool (MPP) today announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries1,2...
Pfizer Inc. and BioNTech SE today announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing the magnitude and breadth of the immune response that could better protect against COVID-19...
Merck
News releases - No new digest announcements identified

Moderna
Press Releases
29 July, 2022

Nanogen
News - No new digest announcements identified

Novartis
News - No new digest announcements identified

Novavax
Press Releases
Jul 29, 2022
Novavax Requests Expanded Emergency Use Listing with World Health Organization for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17

Jul 26, 2022
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Jul 26, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

Pfizer
Recent Press Releases
07.27.2022
Updates and Statements
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified
Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBP/BIBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

SK Biosciences
Press Releases
If approved, SK bioscience will accelerate to apply for emergency use listing (EUL) to the World H... 2022.07.29

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - No new digest announcements identified [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  [No website identified]

* * * * *
* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 2
https://www.tandfonline.com/toc/uabr21/current
Evaluating the impact of stay-at-home and quarantine measures on COVID-19 spread
During the early stage of the COVID-19 pandemic, many countries implemented non-pharmaceutical interventions (NPIs) to control the transmission of SARS-CoV-2, the causative pathogen of COVID-19. Among those NP...
The converging influence of social, economic and psychological factors on public responsiveness to the COVID-19 pandemic in South Africa

This study assessed the influence of social, economic, and psychological factors on South African’s responsiveness to the COVID-19 pandemic. Although the South African government responded quickly to manage th...

Factors contributing to the sharing of COVID-19 health information amongst refugee communities in a regional area of Australia: a qualitative study

The COVID-19 pandemic has had a disproportionate impact on culturally and linguistically diverse (CALD) groups worldwide. Newly emerging CALD populations formed by recently arrived refugees are predisposed to ...
The integral partnership of biology and technology

Editorial

Technology is a powerful partner in biology and biomedicine, allowing for the exploration of frontiers previously beyond our physical and conceptual reach. Transformative discoveries have often come together with the development and clever deployment of a new method, tool, or computational approach. Reciprocally, technological advances are often inspired by biological systems or the need to develop a method to tackle a biological problem. This synergistic relationship is at its most impactful when applied to explore fundamental questions in biology and medicine that have eluded our understanding.

Featured Article

Establishing a blockchain-enabled Indigenous data sovereignty framework for genomic data

Tim K. Mackey, Alec J. Calac, B S Chenna Keshava, Joseph Yracheta, Krystal S. Tsosie, Keolu Fox

Technological advances have enabled the rapid generation of health and genomic data, though rarely do these technologies account for the values and priorities of marginalized communities. In this commentary, we conceptualize a blockchain genomics data framework built out of the concept of Indigenous Data Sovereignty.

Reviews

Cancer vaccines: Building a bridge over troubled waters

MacLean C. Sellars, Catherine J. Wu, Edward F. Fritsch
For many decades, vaccines have provided effective protection against a variety of infectious diseases. Attention is now focused on utilizing the power of the immune system to target tumors through the development of cancer vaccines. This review provides a background in how the immune system responds to cancer and how these immune responses can be harnessed for cancer vaccines and highlights some of the remaining challenges.
Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2022 - Volume 35 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 2 Pages: 63-122 June 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 5, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 3 - June 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 3 Pages: 587-852 July 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23 Issue 7 5 July 2022
https://www.embopress.org/toc/14693178/current
[New issue; No digest content identified]
Emerging Infectious Diseases
Volume 28, Number 7—July 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 39  June 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 4  Pages: 1-44  July–August 2022
https://onlinelibrary.wiley.com/toc/25782363/current

Big data research and group harm • Privacy and microbiome research • Trustworthy research
Articles
Perspectives from a Predominantly African American Community about Biobank Research and a Biobank Consent Form
Laura K. Sedig, E. Hill De Loney, Sarah B. Bailey, Kayte Spector-Bagdady, Bianca Ghita, Lydia Koh Krienke, Raymond Hutchinson
Open Access

Big Health Data Research and Group Harm: The Scope of IRB Review
Megan Doerr, Sara Meeder
Pages: 34-38
First Published: 08 July 2022
Free Access

Developing and Implementing Electronic Consent Procedures in Response to Covid-19 Restrictions
Julie R. Bromberg, Evelyn Nimaja, Andrew W. Kiragu, Karla A. Lawson, Lois Lee, Isam W. Nasr, Charles Pruitt, Stephanie M. Ruest, Michael J. Mello
Pages: 39-44
First Published: 08 July 2022

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

**Ethics, Medicine and Public Health**
Volume 22  Pages 1-104 (June 2022)
[Reviewed earlier]

**The European Journal of Public Health**
Volume 32, Issue 3, June 2022
https://academic.oup.com/eurpub/issue/32/3
[Reviewed earlier]

**Expert Review of Vaccines**
Vol 21 (6) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

**Foreign Affairs**
Volume 101, Number 3  May/June 2022
https://www.foreignaffairs.com/issues/2022/101/3
[Reviewed earlier]

**Foreign Policy**
Spring 2022
https://foreignpolicy.com/the-magazine/?issue_id=411130839
[Reviewed earlier]

**Forum for Development Studies**
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

**Genetics in Medicines**
Volume 24, Issue 7  Pages A1-A6, 1379-1592 (July 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/7
[Reviewed earlier]

**Genome Medicine**
https://genomemedicine.biomedcentral.com/articles
Global Health Action  
Volume 15, Issue 1 (2022)  
https://www.tandfonline.com/toc/zgha20/current?nav=tocList  
[Reviewed earlier]

Global Health: Science and Practice (GHSP)  
Vol. 10, No. 3  
June 29, 2022  
http://www.ghspjournal.org/content/current  
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA  
https://www.loc.gov/collections/global-legal-monitor/  
[Accessed  30 Jul 2022]  
[No new digest content identified]

Global Public Health  
Volume 17, Issue 7 (2022)  
http://www.tandfonline.com/toc/rgph20/current  
[Reviewed earlier]

Globalization and Health  
http://www.globalizationandhealth.com/  
[Accessed  30 Jul 2022]  
[No new digest content identified]

Health and Human Rights  
Volume 24, Issue 1, June 2022  
[Reviewed earlier]

Health Economics, Policy and Law  
Volume 17 - Issue 3 - July 2022  
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue  
[Reviewed earlier]

Health Policy and Planning  
Volume 37, Issue 6, June 2022
Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 30 Jul 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 13-14 / July 2022
https://www.liebertpub.com/toc/hum/33/13-14
[New issue; No digest content identified]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Jul 12, 2022  Volume 55  Issue 7  p1139-1328
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 30 Jul 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 30 Jul 2022]
[No new digest content identified]

International Health
Volume 14, Issue 4, July 2022
Changes in the Relationship Between Income and Life Expectancy Before and During the COVID-19 Pandemic, California, 2015-2021
Hannes Schwandt, PhD; Janet Currie, PhD; Till von Wachter, PhD; et al.
free access
This study examines changes in the income–life expectancy gradient between 2015 and 2021, including the period before and during the first 2 years of the pandemic, and how changes differed across racial and ethnic populations.
JAMA Pediatrics
July 2022, Vol 176, No. 7, Pages 630-730
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
July 2022 - Volume 20 - Issue 7
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
August 2022 Volume 71 Issue 2 p141-250
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 74 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 4, August 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-4
[Reviewed earlier]

Journal of Development Economics
Volume 157 June 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 3, July 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2022 - Volume 76 - 6
https://jech.bmj.com/content/76/6
[Reviewed earlier]
Journal of Evidence-Based Medicine
Volume 15, Issue 2  Pages: 73-179  June 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[New issue; No digest content identified]

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 2, May 2022
https://muse.jhu.edu/issue/47787
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 3, June 2022
https://link.springer.com/journal/10903/volumes-and-issues/24-3
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022  Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
[Reviewed earlier]

Journal of International Development
Volume 34, Issue 4  Pages: 693-930  May 2022
https://onlinelibrary.wiley.com/toc/10991328/current
Special Issue: Long run effects of Covid-19 on developing countries
Issue Edited by: Sanghamitra Bandyopadhyay, Krishna Vadlamannati
[Reviewed earlier]
Journal of Medical Ethics
July 2022 - Volume 48 - 7
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 2 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
July 2022  Volume 246  p1-294
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 30 Jul 2022]
[No digest content identified]

Journal of Public Health Management & Practice
September/October 2022 - Volume 28 - Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 2, June 2022
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
July 2022  Volume 19  Issue 192
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]
Monkeypox: a global wake-up call

The Lancet

WHO's declaration on July 23 that the current monkeypox outbreak constitutes a Public Health Emergency of International Concern (PHEIC) was unprecedented. It is the seventh such declaration, but the first made against the advice of a majority of the emergency committee (nine were against, six were for). Dr Tedros' decision is a brave one. It needs to serve as a global wake-up call. The question is whether it will prompt the escalated efforts required to control the outbreak.

Dr Tedros gave three broad reasons for his decision. “We have an outbreak that has spread around the world rapidly, through new modes of transmission about which we understand too little, and which meets the criteria in the International Health Regulations.” The details make for a compelling case. So far this year, up to July 22, 16,016 cases have been reported from 75 countries. Where monkeypox is endemic, such as in DR Congo, large new outbreaks have been reported in diverse populations. Outside of west and central Africa, the outbreak is concentrated, for now, in men-who-have-sex-with-men (MSM). Why the disease’s epidemiology has changed is still unclear, as are many other aspects of the outbreak. Recent case series from non-endemic countries have shown differences in clinical features compared with previous reports. Lethargy and fever seem to be less common, and several patients have no prodromal symptoms. Skin lesions are found predominantly in genital or perianal areas. Transmission is known to occur through skin-to-skin contact, but monkeypox DNA has been found in patients’ seminal fluid—whether it represents replication-competent virus remains unknown. The rapid worldwide spread of a disease, for reasons we are unsure of, was clearly an over-riding concern for Dr Tedros. An urgent energised research effort is now needed to understand these and other issues related to the outbreak.

Countries must strengthen public health preparedness and response. Case definitions should be updated and harmonised as new data emerge, with heightened surveillance, case detection, and contact tracing. Patients need to be supported in isolation and treatment, and targeted immunisation might be needed for people at high risk of exposure. Recent experience with COVID-19 might help countries institute these measures but many health systems are at breaking point already. There is a risk too that the public is fatigued by talk of pandemics and their control. Misinformation about monkeypox has already begun to circulate. The public need to be engaged and targeted risk-communication strategies developed. Monkeypox is not COVID-19. The R0 is around 1, and
transmission mechanisms are entirely different. The clade of monkeypox that seems to be responsible for the outbreak largely causes mild self-limiting illness, although patients have been admitted to hospital, mainly for pain. Ensuring wide understanding of these points is key for managing public anxiety.

Engagement among many MSM has been high since the outbreak started, and this population is—as ever—keen to take care of its health (and do their part to protect others). Countries that criminalise homosexuality and marginalise LGBTI+ communities risk both patients’ wellbeing and chances of controlling transmission. Stigma and discrimination need to be fought. It would be wrong to categorise monkeypox as a disease of MSM.

The expedited pathways for research, development, regulatory approval, and manufacturing of medical countermeasures developed for COVID-19 should be repurposed for monkeypox. A lack of diagnostic tests is hampering case identification in some countries. Tecovirimat, originally produced to treat smallpox, has been licenced by European regulators for monkeypox, but not yet by the US FDA. Other promising treatments, such as cidofovir and brincidofovir, require clinical study. A monkeypox vaccine (sold as Imvanex in Europe and Jynneos in the USA) has been approved, but supplies of both treatments and vaccines are extremely limited. WHO will have to take a much more muscular approach to ensure global access and avoid the inequities of the COVID-19 response.

Whether or not you agree with WHO's decision, there has undoubtedly been a missed opportunity. Monkeypox is not new. It has been causing illness and death in large numbers for decades. Specialists have long called for affordable countermeasures, strengthened surveillance, and more study. But like Ebola and Zika, monkeypox only commands global attention when it hits high-income countries with predominantly White populations. As a result, the window of opportunity to prevent monkeypox becoming established in communities worldwide is closing. Now is a key moment. It warrants the strongest medical, scientific, and political global effort.

Comment
A new paradigm is needed for financing the pandemic fund
Simon Reid-Henry, et al.

The Lancet Child & Adolescent Health
Jul 2022 Volume 6 Number 7 p445-508, e21
https://www.thelancet.com/journals/lanchi/issue/current
Articles
[Reviewed earlier]

Lancet Digital Health
Aug 2022 Volume 4 Number 8 e566-e626
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Aug 2022 Volume 10 Number 8 e1073-e1208
Monkeypox: wealthy countries must avoid their COVID-19 mistakes
Having ignored the disease for decades, high-income countries must share vaccines and treatments quickly with other nations.

**Nature Biotechnology**
Volume 40 Issue 7, July 2022  
[https://www.nature.com/nbt/volumes/40/issues/7](https://www.nature.com/nbt/volumes/40/issues/7)  
[Reviewed earlier]

**Nature Communications**  
https://www.nature.com/subjects/health-sciences/ncomms  
(Accessed 30 Jul 2022)  
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 7, July 2022  
[https://www.nature.com/ng/volumes/54/issues/7](https://www.nature.com/ng/volumes/54/issues/7)  
[Reviewed earlier]

**Nature Human Behaviour**
Volume 6 Issue 6, June 2022  
[https://www.nature.com/nathumbehav/volumes/6/issues/6](https://www.nature.com/nathumbehav/volumes/6/issues/6)  
[Reviewed earlier]

**Nature Medicine**
Volume 28 Issue 7, July 2022  
[https://www.nature.com/nm/volumes/28/issues/7](https://www.nature.com/nm/volumes/28/issues/7)  
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 23 Issue 7, July 2022  
[https://www.nature.com/nrg/volumes/23/issues/7](https://www.nature.com/nrg/volumes/23/issues/7)  
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 22 Issue 7, July 2022  
[https://www.nature.com/nri/volumes/22/issues/7](https://www.nature.com/nri/volumes/22/issues/7)  
[New issue; No digest content identified]

**Nature Reviews Drug Discovery**
Volume 21 Issue 7, July 2022
New England Journal of Medicine
July 28, 2022  Vol. 387 No. 4
https://www.nejm.org/toc/nejm/medical-journal

Editorials
Audio Interview: Reinventing the Research Infrastructure to Address Covid-19
E.J. Rubin, L.R. Baden, J.S. Currier, and S. Morrissey

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed  30 Jul 2022]

Article
26 Jul 2022
Rational development of a combined mRNA vaccine against COVID-19 and influenza
Qing Ye, Mei Wu, Cheng-Feng Qin

Pediatrics
Volume 150, Issue 1  July 2022
https://publications.aap.org/pediatrics/issue/150/1
[Reviewed earlier]

PharmacoEconomics
Volume 40, issue 7, July 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-7
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed  30 Jul 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed  30 Jul 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed  30 Jul 2022)
Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system–based cross-sectional study
Inmaculada Hernandez, Sean Dickson, Shangbin Tang, Nico Gabriel, Lucas A. Berenbrok, Jingchuan Guo
Research Article | published 28 Jul 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004069

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study
Marco Massari, Stefania Spila Alegiani, Cristina Morciano, Matteo Spuri, Pasquale Marchione, Patrizia Felicetti, Valeria Belleudi, Francesca Romana Poggi, Marco Lazzeretti, Michele Ercolanoni, Elena Clagnan, Emanuela Bovo, Gianluca Trifirò, Ugo Moretti, Giuseppe Monaco, Olivia Leoni, Roberto Da Cas, Fiorella Petronzelli, Loriana Tartaglia, Nadia Mores, Giovanna Zanoni, Paola Rossi, Sarah Samez, Cristina Zappetti, Anna Rosa Marra, Francesca Menniti Ippolito, on behalf of the TheShinISS-Vax|COVID Surveillance Group
Research Article | published 28 Jul 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004056

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 30 Jul 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 30 Jul 2022]
Determinants of personal vaccination hesitancy before and after the mid-2021 COVID-19 outbreak in Taiwan
Hsuan-Wei Lee, Cheng-Han Leng, Ta-Chien Chan
Research Article | published 29 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270349

Vaccine discourse during the onset of the COVID-19 pandemic: Topical structure and source patterns informing efforts to combat vaccine hesitancy
Juwon Hwang, Min-Hsin Su, Xiaoya Jiang, Ruixue Lian, Arina Tveleneva, Dhavan Shah
Research Article | published 27 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0271394

COVID-19 vaccination policies under uncertain transmission characteristics using stochastic programming
Krishna Reddy Gujjula, Jinyue Gong, Brittany Segundo, Lewis Ntiamo
Research Article | published 22 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270524
Research Article
July 11, 2022
Coronavirus (COVID-19)

*The influence of social norms varies with “others” groups: Evidence from COVID-19 vaccination intentions*

The theory that health behaviors spread through social groups implies that efforts to control COVID-19 through vaccination will succeed if people believe that others in their groups are getting vaccinated. But “others” can refer to many groups, including ...

Nathaniel Rabb, Jake Bowers,[... ] David Yokum

Prehospital & Disaster Medicine
Volume 37 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[New issue; No digest content identified]
Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 3, May/June 2022
https://journals.sagepub.com/toc/phrg/137/3
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 7, June 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 18 Issue 3, July 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 30 Jul 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 6  Pages: 1149-1364  June 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Bayesian Networks for Risk Analysis and Decision Support
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 30 Jul 2022]
Review
Prevalence and Determinants of COVID-19 Vaccine Hesitancy Among the Ethiopian Population: A Systematic Review
Yehualashet DE, Seboka BT, Tesfa GA, Mamo TT, Yawo MN, Hailegebreal S
Risk Management and Healthcare Policy 2022, 15:1433-1445
Published Date: 29 July 2022

Science
Volume 377| Issue 6605| 29 Jul 2022
https://www.science.org/toc/science/current
Policy Forum
A treaty to break the pandemic cycle
BY Alexandra L. Phelan, Colin J. Carlson
14 Jul 2022: 475-477
An evidence-based treaty must balance prevention, preparedness, response, and repair
Twelve elements of a pandemic treaty
A successful treaty must balance several aims between prevention (reducing both spillover and pandemic risk) and response (reducing pandemic impacts and improving recovery and resilience).
Reduce spillover risk
Planetary health solutions (global)
One Health solutions (local)
Zoonotic risk assessment
Reduce pandemic risk
Surveillance and assessment
Biomedical R&D and production
Health systems strengthening
Reduce pandemic impacts
Equitable access to global goods
Emergency legal preparedness
Least restrictive measures
Recovery and resilience
Adaptive governance
Accountability and transparency
Reduce inequities and injustice

Science and Engineering Ethics
Volume 28, issue 3, June 2022
[Reviewed earlier]

Science Translational Medicine
Volume 14| Issue 655| 27 Jul 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]
Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 30 Jul 2022]
**Paper 1: Demand-driven rapid reviews for health policy and systems decision-making: lessons from Lebanon, Ethiopia, and South Africa on researchers and policymakers’ experiences**
Rapid reviews have emerged as an approach to provide contextualized evidence in a timely and efficient manner. Three rapid review centers were established in Ethiopia, Lebanon, and South Africa through the All...
Authors: Rhona M. Mijumbi-Deve, Ismael Kawooya, Edward Kayongo, Rose Izizinga, Hadis Mamuye, Krystle Amog and Etienne V. Langlois
Citation: Systematic Reviews 2022 11:154
Content type: Research Published on: 30 July 2022

Theoretical Medicine and Bioethics
Volume 43, issue 1, February 2022
https://link.springer.com/journal/11017/volumes-and-issues/43-1
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 48 July–August 2022
Review article Abstract only
**Historical review: Towards the 50th anniversary of the last major smallpox outbreak (Yugoslavia, 1972)**
Irena Ilic, Milena Ilic
Article 102327

Research article Full text access
**High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries**
Rafael Dal-Ré, Rita Banzi, Sören L. Becker, Odile Launay, Androula Pavli
Article 102321

Research article Full text access
**High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries**
Rafael Dal-Ré, Rita Banzi, Sören L. Becker, Odile Launay, Androula Pavli
Article 102321
Discussion  Full text access
Impact of vaccination during pregnancy on infants’ immune responses to vaccinations-
definitions and statistical approaches
Kirsten Maertens, Elke Leuridan, Flor M. Munoz, Petra Zimmermann, ... Bahaa Abu-Rayba
Pages 4292-4295

Discussion  Full text access
COVID-19 vaccine safety monitoring in low and middle income countries – Time for a bold
new approach
Walter Straus, Harvey Rubin
Pages 4301-4302

Review article  Abstract only
Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from
pediatric influenza vaccine efficacy trials
Jordan B. Braunfeld, Heather N. Carson, Sarah R. Williams, Lauren M. Schwartz, ... Justin R. Ortiz
Pages 4339-4347

Review article  Full text access
Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest
Paul Moss, Francis Berenbaum, Giuseppe Curigliano, Ayelet Grupper, ... Shanti Pather
Pages 4348-4360

Review article  Abstract only
Understanding predictors of pneumococcal vaccine uptake in older adults aged 65 years
and older in high-income countries across the globe: A scoping review
Sharifa Nasreen, Gebremedhin B. Gebretekele, Meghan Lynch, Anna Kurdina, ... Sara Allin
Pages 4380-4393

Research article  Full text access
A socio-ecological perspective on parents’ intentions to vaccinate their children against
COVID-19
Lauren Dayton, Jacob Miller, Justin Strickland, Melissa Davey-Rothwell, Carl Latkin
Pages 4432-4439

Research article  Full text access
The effect of health literacy on COVID-19 vaccine hesitancy among community population
in China: The moderating role of stress
Research article  Full text access
Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines
Ashley Gambrell, Maria Sundaram, Robert A. Bednarczyk
Pages 4574-4579

Research article  Open access
Countering vaccine hesitancy through medical expert endorsement
Piero Ronzani, Folco Panizza, Carlo Martini, Lucia Savadori, Matteo Motterlini
Pages 4635-4643

Research article  Abstract only
Disparities in Human Papillomavirus vaccination coverage among adolescents in Australia: A geospatial analysis
Gustavo Hermes Soares, Sneha Sethi, Joanne Hedges, Lisa Jamieson
Pages 4644-4653

Value in Health
July 2022  Volume 25  Issue 7  p1063-1256
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

::::
:::
:::

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research
Research Article metrics AWAITING PEER REVIEW
Theory-driven formative research to support development of a pre-exposure prophylaxis (PrEP) demand creation campaign among young women in a South-African township
[version 1; peer review: awaiting peer review]
Jessie de Witt Huberts, Val Curtis, Connie Celum, Jennifer Morton, Linda-Gail Bekker, Katherine Gill, Robert Aunger
Peer Reviewers Invited
Funder
Bill and Melinda Gates Foundation
PUBLISHED 27 Jul 2022

Study Protocol metrics AWAITING PEER REVIEW
Creation, dissemination, and evaluation of videos to promote COVID-19 vaccination in India: A research protocol [version 1; peer review: awaiting peer review]
Selected Research

**Key population size, HIV prevalence, and ART coverage in sub-Saharan Africa: systematic collation and synthesis of survey data**

Oliver Stevens, Keith Sabin, Sonia Arias Garcia, Rebecca Anderson, Kalai Willis, Abu Abdul-Quader, Anne McIntyre, Elizabeth Fearon, Emilie Grard, Alice Stewart-Brown, Frances Cowan, Louisa Degenhardt, Jinkou Zhao, Avi Hakim, Katherine Rucinski, Isabel Sathane, Makini Boothe, Lydia Atuhuire, Peter Nyesulu, Lucy Platt, Brian Rice, Wolfgang Hladik, Stefan Baral, Mary Mahy, Jeffrey W. Eaton

medRxiv 2022.07.27.22278071; doi: https://doi.org/10.1101/2022.07.27.22278071

**Evaluation of the safety and immunogenicity of fractional intradermal COVID-19 vaccines as a booster: A pilot study**

Suvimol Niyomnaitham, Somruedee Chatsiricharoenkul, Zheng Quan Toh, Sansnee Senawong, Chatkamol Pheerapanyawaranun, Supaporn Phumiamorn, Paul V. Licciardi, Kulkanya Chokephaibulkit

medRxiv 2022.07.27.22278116; doi: https://doi.org/10.1101/2022.07.27.22278116

**Social contact patterns during the COVID-19 pandemic in 21 European countries: evidence from a two-year study**


medRxiv 2022.07.25.22277998; doi: https://doi.org/10.1101/2022.07.25.22277998

**The human host response to monkeypox infection: a proteomic case series study**

Ziyue Wang, Pinkus Tober-Lau, Vadim Farztdinov, Oliver Lemke, Torsten Schwecke, Sarah Steinbrecher, Julia Muenzner, Helene Kriedemann, Leif Erik Sander, Johannes Hartl, Michael Mülleder, Markus Ralser, Florian Kurth

medRxiv 2022.07.27.22278027; doi: https://doi.org/10.1101/2022.07.27.22278027

**Prosocial motivation for vaccination**
Correlates of protection for booster doses of the BNT162b2 vaccine
medRxiv 2022.07.16.22277626; doi: https://doi.org/10.1101/2022.07.16.22277626

Reproduction number of monkeypox in the early stage of the 2022 multi-country outbreak
Zhanwei Du, Zengyang Shao, Yuan Bai, Lin Wang, Jose L Herrera-Diestra, Spencer J. Fox, Zeynep Ertem, Eric H. Y. Lau, Benjamin J. Cowling

Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

Detection of monkeypox viral DNA in a routine wastewater monitoring program
Marlene K. Wolfe, Dorothea Duong, Bridgette Hughes, Vikram Chan-Herur, Bradley J. White, Alexandria B. Boehm
medRxiv 2022.07.25.22278043; doi: https://doi.org/10.1101/2022.07.25.22278043

Cost-effectiveness analysis of a maternal pneumococcal vaccine in low-income, high-burden settings such as Sierra Leone
Gizem M. Bilgin, Syarifah Liza Munira, Kamalini Lokuge, Kathryn Glass
medRxiv 2022.07.25.22278016; doi: https://doi.org/10.1101/2022.07.25.22278016

Highlighting the importance of semantics in COVID-19 fake news detection using a CNN hashmap color-based method
Maryam El Azhari
medRxiv 2022.07.24.22277975; doi: https://doi.org/10.1101/2022.07.24.22277975

Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: findings from a multi-wave study
Noura Salibi, Sawsan Abdulrahim, Maria El Haddad, Berthe Abi Zeid, Marwan F. Alawieh, Zeinab Ramadan, Hala Ghattas, Stephen J. McCall
medRxiv 2022.07.23.22277948; doi: https://doi.org/10.1101/2022.07.23.22277948
Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global nature of the pandemics.

Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2021 the database contains 13,484 projects, funded by 285 funders, taking place across 156 countries representing an investment of at least $5.1 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers.

This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.

Results: In this version six analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version five) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries).

Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps
both funders and researchers to prioritise resources to areas where there is continued unmet research need. 

Project funder. The 13,484 projects included in the latest version of the tracker comprises of data compiled from 285 research funders based in 53 different countries representing an investment of at least $5.1 billion (funding amounts only available for 58.2% of projects) (Figure 2). This represents an increase of more than 10% in the number of funders (previously 255 funders based in 51 countries) since the previous version of the analysis.

Open Letter metrics Revised

Integrating economic and health evidence to inform Covid-19 policy in low- and middle-income countries [version 2; peer review: 2 approved with reservations] 
Anna Vassall, Sedona Sweeney, Edwine Barasa, Shankar Prinja, Marcus R Keogh-Brown, Henning Tarp Jensen, Richard Smith, Rob Baltussen, Rosalind M Eggo, Mark Jit
Peer Reviewers Kalipso Chalkidou; Sujata Mishra and Beverley Essue

Funders
Wellcome Trust
Department for International Development, UK Government

LATEST VERSION PUBLISHED 25 Jul 2022

* * * * *

Think Tanks

Brookings [to 30 Jul 2022]
http://www.brookings.edu/
Accessed 30 Jul 2022

Latest Research
Technology & Innovation

The roadmap to telehealth efficacy: Care, health, and digital equities
Nicol Turner Lee, Niam Yaraghi, and Samantha Lai
Monday, July 25, 2022

Center for Global Development [to 25 Jun 2022]
https://www.cgdev.org/

All Research [Selected]
[No new digest content identified]

Chatham House [to 30 Jul 2022]
https://www.chathamhouse.org/

Interview
Disinformation is a high-stake game threatening freedom
In the second of a series of interviews with the Queen Elizabeth II Academy Faculty, Jessica Cecil examines solutions to disinformation eroding trust in democratic leadership.
12 July 2022

**CSIS** [to 30 Jul 2022]
https://www.csis.org/
Selected Reports/Content
[No new digest content identified]

**Kaiser Family Foundation**
https://www.kff.org/search/?post_type=press-release
Accessed 30 Jul 2022
July 27, 2022 News Release
**Donor Governments Spent US$7.5 Billion on Efforts to Combat HIV/AIDS Globally in 2021, Largely Flat Amid the COVID-19 Pandemic, KFF-UNAID Report Finds**
A new report from KFF (Kaiser Family Foundation) and The Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor governments disbursed US$7.5 billion in 2021 to combat HIV in low- and middle-income countries, largely flat amid the COVID-19 pandemic and essentially matching 2008 levels, against a backdrop of growing...

July 26, 2022 News Release
**43% of Parents with Children Under 5 Newly Eligible for a COVID-19 Vaccine Say They Will “Definitely Not” Get Them Vaccinated**
Most Parents Open to Getting Their Young Child Vaccinated Haven’t Yet Spoken to Their Pediatrician
Most parents of young children newly eligible for a COVID-19 vaccine are reluctant to get them vaccinated, including 43% who say they will “definitely not” do so, a new KFF COVID-19 Vaccine Monitor survey finds...

**ODI [Overseas Development Institute]** [to 30 Jul 2022]
Publications
**Women leading local humanitarian response during the Covid-19 pandemic**
27 July 2022
Working papers

**Pew Research Center** [to 30 Jul 2022]
https://www.pewresearch.org/
Latest Publications
**Short Read** | Jul 28, 2022
**Home births rose 19% in 2020 as pandemic hit the U.S.**
While the total number of U.S. births declined at the end of 2020 and beginning of 2021, the number of births at home rose.
This brochure describes RAND’s standards for high-quality and objective research. Jul 25, 2022

RAND's standards for high-quality and objective research and analysis describe how our research embodies our core values of quality and objectivity. The standards should be evident in the conduct of our research and analysis and in our research products. The standards substantiate our commitment to producing high-caliber, high-utility policy research and analysis.

Urban Institute  [to 30 Jul 2022]  
https://www.urban.org/publications

New Research Publications
[No new digest content identified]

World Economic Forum  [to 30 Jul 2022]  
https://agenda.weforum.org/news/
[No new digest content identified]

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *
* * * * *